3rd Quarter - Report — ILLUMINA, INC. for ILLUMINA, INC. (2022)

Firm

ILLUMINA, INC.

Client

ILLUMINA, INC.

Income

—

Expenses

$1,380,000

Expense method

A: Lobbying Disclosure Act definitions

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

H.R. 4128/S. 2209: Verifying Accurate Leading-edge IVCT Development (VALID) Act of 2021; all provisions H.R. 6000: Cures 2.0 Act; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding H.R.7667: Food and Drug Amendments of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement H.R. 8295/S. 4659: Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2023; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding S. 2022: Ending the Diagnostic Odyssey Act of 2021; all provisions S. 3799: Prepare for and Respond to Existing Viruses, Emerging New Threats, and Pandemics (PREVENT Pandemics) Act; all provisions S. 4348: Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act of 2022; discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding P.L.117-180: Making continuing appropriations for fiscal year 2023, and for other purposes (H.R. 6833); discussions related to genomics, sequencing, the applications for sequencing including in rare disease and related reimbursement, CDC surveillance funding and National Institutes of Health funding

Lobbyist	Covered position, as disclosed
BRIAN CHRISTOPHER TOOHEY	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4128 (117th), S. 2022 (117th), H.R. 8295 (117th), S. 4348 (117th), H.R. 7667 (117th), H.R. 6000 (117th), S. 4659 (117th), S. 2209 (117th), S. 3799 (117th), H.R. 6833 (117th)

Government Issues GOV

General discussions related to competition, access, and regulatory actions regarding Multi-Cancer Early Detection technology General discussions related to genomic surveillance and pandemic preparedness General discussions related to the Cancer Moonshot Initiative General discussion related to President Biden's Executive Order on Advancing Biotechnology and Biomanufacturing Innovation for a Sustainable, Safe, and Secure American Bioeconomy

Lobbyist	Covered position, as disclosed
BRIAN CHRISTOPHER TOOHEY	—

Contacted: SENATE; Office of Science & Technology Policy (OSTP); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Executive Office of the President (EOP); Health & Human Services, Dept of (HHS); Natl Security Council (NSC)

Trade (domestic/foreign) TRD

H.R. 4521: United States Innovation and Competition Act of 2021; all provisions S. 1260: United States Innovation and Competition Act of 2021; all provisions H.R. 4346: The CHIPS and Science Act of 2022; all provisions

Lobbyist	Covered position, as disclosed
BRIAN CHRISTOPHER TOOHEY	—

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4346 (117th), S. 1260 (117th), H.R. 4521 (117th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.